Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

Hepatology

Volumn 42, Issue 3, 2005, Pages 724-731

  Horsmans, Yves ^a   Berg, Thomas ^b   Desager, Jean Pierre ^a   Mueller, Tobias ^b   Schott, Eckart ^b   Fletcher, Simon P ^c   Steffy, Kevin R ^c   Bauman, Lisa A ^c   Kerr, Bradley M ^c   Averett, Devron R ^c  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ISATORIBINE; PEGINTERFERON ALPHA2B; RIBAVIRIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CHILL; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RESISTANCE; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; MALE; NAUSEA; NUCLEOTIDE SEQUENCE; PHARMACODYNAMICS; PRIORITY JOURNAL; VIRUS LOAD; VIRUS MUTATION; VOMITING;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GUANOSINE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; RNA, VIRAL; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTORS; VIRAL LOAD;

EID: 24144448068     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20839     Document Type: Article

References (43)

1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004;39:1147-1171.
2. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362:2095-2100.
3. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002;123:2082-2099.
4. Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1996;8:324-328.
5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
7. Pawlotsky JM, McHutchison JG. Hepatitis C: development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. HEPATOLOGY 2004;39:554-567.
8. Lindenbach BD, Rice CM. Evasive maneuvers by hepatitis C virus. HEPATOLOGY 2003;38:769-771.
9. Trozzi C, Bartholomew L, Ceccacci A, Biasiol G, Pacini L, Altamura S, et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 2003;77:3669-3679.
10. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-2l6.
11. Netea MG, van der Graaf C, Van der Meer JW, Kullberg BJ. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol 2004;75:749-755.
12. Beutler B. Inferences, questions and possibilities in toll-like receptor signalling. Nature 2004;430:257-263.
13. O'Neill LA. Immunology. After the toll rush. Science 2004;303:1481-1482.
14. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of toll-like receptor 7. Proc Natl Acad Sci U S A 2003; 100:6646-6651.
15. Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Ampenberger F, Gellert T, et al. The toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003;33:2987-2997.
16. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003;85:85-95.
17. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200.
18. Nagahara K, Anderson JD, Kini GD, Dalley NK, Larson SB, Smee DF, et al. Thiazolo[4,5-d]pyrimidine nucleosides: the synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents. J Med Chem 1990;33:407-415.
19. Smee DF, Alaghamandan HA, Cottam HB, Sharma BS, Jolley WB, Robins RK. Broad-spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine, a novel immunopotentiating agent. Antimicrob Agents Chemother 1989;33:1487-1492.
20. Smee DF, Alaghamandan HA, Cottam HB, Jolley WB, Robbins RK. Antiviral activity of the novel immune modulator 7-thia-8-oxoguanosine. J Biol Response Mod 1990;9:24-32.
21. Smee DF, Huffman JH, Gessaman AC, Huggins JW, Sidwell RW. Prophylactic and therapeutic activities of 7-thia-8-oxoguanosine against Punta Toro virus infections in mice. Antiviral Res 1991;15:229-239.
22. Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alpha-2b plus ribavirin. HEPATOLOGY 2002;35:930-936.
23. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000;68:556-567.
24. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. HEPATOLOGY 2003;37:1351-1358.
25. Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C; a randomized, controlled study. Antivir Ther 2004;9:491-497.
26. Solinas A, Cossu P, Poddighe P, Tocco A, Deplano A, Garrucciu G, et al. Changes of serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C. Liver 1993;13:253-258.
27. Schenker S, Cutler D, Finch J, Tamburro CH, Affrime M, Sabo R, et al. Activity and tolerance of a continuous subcutaneous infusion of interferon-alpha2b in patients with chronic hepatitis C. J Interferon Cytokine Res 1997;17:665-670.
28. Murashima S, Kumashiro R, Ide T, Miyajima I, Hino T, Koga Y, et al. Effect of interferon treatment on serum 2′,5′-oligoadenylate synthetase levels in hepatitis C-infected patients. J Med Virol 2000;62:185-190.
29. MacQuillan GC, Mamotte C, Reed WD, Jeffrey GP, Allan JE. Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. J Med Virol 2003;70:219-227.
30. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002;3:175-87.
31. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002;168:3195-3204.
32. Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46:563-570.
33. Hong Z, Cameron CE. Pleiotropic mechanisms of ribavirin antiviral activities. Prog Drug Res 2002;59:41-69.
34. Hong Z. The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact? HEPATOLOGY 2003;38;807-810.
35. Vollmer J, Rankin R, Hartmann H, Jurk M, Samulowitz U, Wader T, et al. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother 2004;48:2314-2317.
36. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004;30: 115-133.
37. Pockros PJ, Patel K, O'Brien C, Tong M, Smith C, Rustgi V, et al. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. HEPATOLOGY 2003;37:1368-1374.
38. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002; 5:375-388.
39. Zuany-Arnorim C, Hastewell J, Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov 2002;1: 797-807.
40. Lawton JA, Ghosh P. Novel therapeutic strategies based on toll-like receptor signaling. Curr Opin Chem Biol 2003;7:446-451.
41. O'Neill LA. Therapeutic targeting of toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 2003;3:396-403.
42. Tran H, Moreno G, Shumack S. Imiquimod as a dermatological therapy. Expert Opin Pharmacother 2004;5:427-438.
43. Pockros P, Tong M, Wright T. A phase IIa placebo-controlled, double blind trial to determine the safety, tolerability, and pk/pd of an oral interferon inducer. Gastroenterology 2003;124(Suppl 1):76A.